More about Procter & Gamble Hygiene and Health Care Limited
Fundamentals for Procter & Gamble Hygiene and Health Care Limited
Regulatory Filings for Procter & Gamble Hygiene and Health Care Limited
The Hidden Cost of India's Electronics Assembly Push: A 40% E-Waste Surge and the Death of Affordable Repair
The Wedding Loan Trap: How India’s Microfinance Boom Turned Housewives Into Ghost Borrowers and Temple Brass Into EMI Cash
From Lifesaving Drugs to Sick Units: The Hidden Energy Crisis Inside India’s Pharma Clusters
From Price Pressures to Profit Power: The MSME Playbook Redefining India’s Economy
Fundamentals for Procter & Gamble Hygiene and Health Care Limited
Business Operations:
Sector: Consumer DefensiveIndustry: Household & Personal Products
Procter & Gamble Hygiene and Health Care Limited engages in the manufacture and sale of branded packaged fast-moving consumer goods in the feminine care and healthcare businesses in India and internationally. It operates through Healthcare Products and Hygiene Products segments. The company provides health care products, including ointments and creams, cough drops, and tablets; and hygiene products, such as feminine hygiene and other skin care hygiene products, as well as feminine care pads. It also offers baby care products comprising nappies, pants, and baby wipes; grooming products; laundry products; hair care products; home care products; and oral care products. The company offers its products under the Vicks, Whisper, Pampers, Ariel, Tide, Gillette, Head & Shoulders, Herbal Essences, Pantene, Ambi Pur, Oral-B, Olay, and Old Spice brand names. It sells its products through mass merchandisers, as well as grocery, membership club, drug, department, and high frequency stores. The company was incorporated in 1964 and is based in Mumbai, India. Procter & Gamble Hygiene and Health Care Limited operates as a subsidiary of The Procter & Gamble Company.
Revenue projections:
Procter & Gamble Hygiene and Health Care Limited's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.
Financial Ratios:
| currentRatio | 0.00000 |
|---|---|
| forwardPE | 34.52321 |
| debtToEquity | 0.22100 |
| earningsGrowth | 0.12200 |
| revenueGrowth | 0.01100 |
| grossMargins | 0.62948 |
| operatingMargins | 0.31088 |
| trailingEps | 220.42000 |
| forwardEps | 298.35000 |
PGHH's positive gross and operating margins highlight its strong profitability. The company's ability to control costs while generating revenue indicates efficient operations and a healthy financial position.
Procter & Gamble Hygiene and Health Care Limited's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.
Price projections:
Price projections for PGHH have been revised down over time, reflecting a less optimistic outlook. Analysts appear to be adjusting their expectations, signaling concerns about the company's ability to sustain its previous growth levels.
Recommendation changes over time:
Analysts are favoring PGHH with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider PGHH as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
₹90 Crore Bet Signals a Massive Shift in India’s Rural Economy
The Hidden Engine of Global Growth: Why India Is Becoming Impossible to Overlook
₹10,000 Crore Deep-Tech Pivot: Why Fund of Funds 2.0 Will Redraw India's Startup Map